Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Winsef (6R,7R)-7-[[2-(2-amino-1,3- thiazol-4-yl)-2...

Synonyms:

Neu, H.C. et al., Washington, J.A. et al., Cormican, M.G. et al., Giamarellos-Bourboulis, E.J. et al., Jones, R.N. et al., et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Winsef

Overall, FK-037 has lower MICs against staphylococci and P. aeruginosa than the currently available iminomethoxy aminothiazolyl cephalosporins and has activity against members of the family Enterobacteriaceae comparable to that of cefepime [1].
The FK-037 MIC90 for Pseudomonas aeruginosa was 4 microgram/ml, compared to 32 microgram/ml for cefepime and ceftazidime and 8 microgram/ml for imipenem [1].
E. cloacae, Citrobacter freundii, and S. aureus stably resistant to FK-037 could be selected by repeated transfer in the presence of FK-037 [1].
In a multicenter study, the MICs of FK-037 for 90% of the strains tested (MIC90s) were < or = 1 microgram/ml for members of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter spp., and Serratia marcescens [2].
Of 98 isolates of homogenous methicillin-resistant Staphylococcus aureus, 55 (56.1%) were inhibited by 8 micrograms of FK-037 per ml, compared to 3.1% for cefepime [1].

High impact information on Winsef

Pharmacokinetics and distribution in tissue of FK-037, a new parenteral cephalosporin [3].
Nonetheless, FK-037 inhibited bacteria possessing TEM-3, -5, and -7 and SHV -5 at less than or equal 8 microgram/ml [1].
In-vitro activity of FK-037, a new parenteral cephalosporin [4].
In vitro activity of FK-037. A parenteral cephalosporin [5].
Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae [6].

Chemical compound and disease context of Winsef

Pseudomonas aeruginosa displayed similar susceptibilities to ceftazidime and FK-037 (MIC90 4 and 8 mg/L respectively) [7].
We have evaluated the in vitro activity of FK-037, a new cephalosporin, cefotaxime, cefpirome, ceftazidime, levofloxacin, and ofloxacin against a collection of 124 isolates from patients with spontaneous bacterial peritonitis [8].

Associations of Winsef with other chemical compounds

In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates [9].

References

In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin. Neu, H.C., Chin, N.X., Huang, H.B. Antimicrob. Agents Chemother. (1993) [Pubmed]
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Washington, J.A., Jones, R.N., Gerlach, E.H., Murray, P.R., Allen, S.D., Knapp, C.C. Antimicrob. Agents Chemother. (1993) [Pubmed]
Pharmacokinetics and distribution in tissue of FK-037, a new parenteral cephalosporin. Wise, R., Andrews, J.M., O'Neill, P., Jolley, A., Fowler, C., Rogge, M.C. Antimicrob. Agents Chemother. (1994) [Pubmed]
In-vitro activity of FK-037, a new parenteral cephalosporin. Jones, R.N., Barrett, M.S., Erwin, M.E. J. Antimicrob. Chemother. (1994) [Pubmed]
In vitro activity of FK-037. A parenteral cephalosporin. Segreti, J., Kraatz, J., Goldman, M., Trenholme, G.M. Diagn. Microbiol. Infect. Dis. (1994) [Pubmed]
Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Jones, R.N., Barrett, M.S., Biedenbach, D.J. Diagn. Microbiol. Infect. Dis. (1994) [Pubmed]
The in-vitro activity of FK-037, a new broad spectrum injectable cephalosporin. Wise, R., Andrews, J.M., Thornber, D. J. Antimicrob. Chemother. (1994) [Pubmed]
In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis. Cormican, M.G., Runyon, B.A., Jones, R.N. Journal of chemotherapy (Florence, Italy) (1995) [Pubmed]
In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Giamarellos-Bourboulis, E.J., Grecka, P., Tsitsika, A., Tympanidou, C., Giamarellou, H. Diagn. Microbiol. Infect. Dis. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg